- Investor Presentation
- Earnings Call Transcripts
- Share holding Structures
- Unclaimed–Dividend & Shares Transferred to IEPF
- BSE & NSE
- Analyst Coverage
- Buy Back 2020
- Investor FAQ
Earnings Call Transcripts
Other Management Call Transcripts
|Research Firms||Analyst||E-mail id|
|Anand Rathi||Rashmi Sanchetifirstname.lastname@example.org|
|BP Equities||Nikhil Shettyemail@example.com|
|Dalal & Broacha||Charulata Gaidhanifirstname.lastname@example.org|
|HDFC Securities .||Amey Chalke||Amey.Chalke@hdfcsec.com|
|KR Chowksy||Hemanshu Srivastavaemail@example.com|
|Motilal Oswal||Kumar Saurabhfirstname.lastname@example.org|
|Motilal Oswal||Jehan Bhadhaemail@example.com|
|Nirmal Bang||Runjhun Jainfirstname.lastname@example.org|
|Spark Capital||Harith Ahamedemail@example.com|
Granules India Limited is a vertically integrated Indian pharmaceutical company, based in Hyderabad, India. We manufacture Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs). As Granules stands today, we are organized based on three segments; the Core business which comprises our 'core molecules- Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol; the New API business that focuses on manufacturing APIs with a focus on vertical integration and the CRAMS segment, which focuses on contract research and manufacturing.
Granules was incorporated in 1984.
Granules went public by listing its shares in 1995.
Granules is traded on the Bombay Stock Exchange under the code 532482 and National Stock Exchange under the symbol GRANULES.
Please visit Investor Section of the Granules' website to download the latest annual report.
The financial year ends on March 31.